Peplin
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Peplin sits in the top decile of US sponsors by registered trial count (#772 of 15,742 sponsors by registered trial count).
Peplin: 19 sponsored US clinical trials, none currently recruiting.
Peplin sponsors 19 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 19 completed. 5 of these trials are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Actinic Keratosis, with 4 trials.
Top-decile sponsor footprint
Peplin ranks in the top decile of sponsors by registered trial count (#772 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
19 of 19 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
19 total, page 1 of 1
PEP005 Gel - Evaluation of Local Tolerability After Exposure to Ingenol Mebutate Gel Followed by Hand Washing in Healthy Subjects
NCT01302925
A Long Term Follow up Study of Patients Who Have Complete Clearance of Their Actinic Keratosis (AK) Lesions at the Day 57 Visit in the PEP005-028 Study
NCT00989313
A Long Term Follow up Study of Patients Who Have Completed the PEP005-016 or PEP005-025 Studies
NCT00953732
A Long Term Follow up Study of Patients Who Have Completed the PEP005-020 Study
NCT00952783
A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations
NCT00942604
A Multi-center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)
NCT00916006
A Multi-Center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)
NCT00915551
A Multi-center Study to Evaluate the Safety and Efficacy of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on Non-head Locations (Trunk and Extremities)
NCT00917306
A Study to Evaluate the Pharmacokinetics of PEP005 (Ingenol Mebutate) Gel, 0.05%, When Applied in a Maximal Use Setting to the Dorsal Aspect of the Forearm in Patients With Actinic Keratosis
NCT00852137
A Study to Evaluate the Photoallergic Potential of PEP005 (Ingenol Mebutate) Gel, 0.01% in Healthy Volunteers
NCT00850681
A Study to Evaluate the Photoirritation Potential of PEP005 (Ingenol Mebutate) Gel, 0.01% in Healthy Volunteers
NCT00850811
A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations
NCT00742391
A Multicenter Study to Evaluate the Safety and Efficacy of PEP005 Topical Gel When Used to Treat Actinic Keratoses on the Head (Face or Scalp)
NCT00700063
Safety and Toleration of PEP005 Topical Gel When Applied to a Treatment Area of up to 100cm2
NCT00659893
A Study to Examine the Safety and Toleration of PEP005 Topical Gel in Patients With Actinic Keratoses on the Top of the Hand
NCT00544297
To Determine the Maximum Tolerated Dose Level (MTD) of PEP005 Topical Gel in Patients With sBCC
NCT00432185
Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses
NCT00375739
Study to Determine the Sensitizing Potential of PEP005 Topical Gel in Healthy Volunteers Using a Repeat Insult Patch Test Design
NCT00357916
Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel
NCT00239135
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 6 |
| Phase 3 | 5 |
Therapeutic Areas
How the Peplin early-phase archive is shaped
19 indexed studies, none listed as recruiting (0% open); 19 completed (100%).
Phase mix: 5 late (III/IV) vs 11 early (I/II) (early-phase heavy).
Top condition: Actinic Keratosis (4 trials), 2 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Peplin: archived-pipeline peers nationwide
Peers matched on 19 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Peplin sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 19 archived trials
- Almirall, S.A. · 19 trials · 5% recruiting
- Bastyr University · 19 trials · 11% recruiting
- Church & Dwight Company · 19 trials · 0% recruiting
- Cordis US · 19 trials · 5% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Peplin page
19 registered trials is a research-attention snapshot, not an endorsement of Peplin or any single study.
- None of Peplin's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Actinic Keratosis is the condition Peplin studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Actinic Keratosis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Peplin pipeline card: 19 registered trials from official public datasets.Report a data error.